Universal Beteiligungs und Servicegesellschaft mbH Buys 6,875 Shares of The Cooper Companies, Inc. $COO

Universal Beteiligungs und Servicegesellschaft mbH grew its stake in The Cooper Companies, Inc. (NASDAQ:COO) by 4.5% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 159,502 shares of the medical device company’s stock after buying an additional 6,875 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH owned 0.08% of Cooper Companies worth $10,935,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in Cooper Companies by 48.9% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,407 shares of the medical device company’s stock worth $1,890,000 after purchasing an additional 7,363 shares during the last quarter. Public Employees Retirement System of Ohio lifted its holdings in Cooper Companies by 2.9% in the second quarter. Public Employees Retirement System of Ohio now owns 61,843 shares of the medical device company’s stock valued at $4,401,000 after buying an additional 1,741 shares during the period. Patton Fund Management Inc. bought a new stake in Cooper Companies during the second quarter valued at $212,000. V Square Quantitative Management LLC grew its holdings in Cooper Companies by 15.4% during the 2nd quarter. V Square Quantitative Management LLC now owns 6,614 shares of the medical device company’s stock worth $471,000 after acquiring an additional 884 shares during the period. Finally, Janney Montgomery Scott LLC raised its position in shares of Cooper Companies by 5.1% in the 2nd quarter. Janney Montgomery Scott LLC now owns 97,394 shares of the medical device company’s stock worth $6,931,000 after acquiring an additional 4,761 shares in the last quarter. 24.39% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research firms recently commented on COO. Mizuho set a $100.00 target price on Cooper Companies and gave the stock an “outperform” rating in a research note on Friday, December 5th. Stifel Nicolaus set a $95.00 price objective on shares of Cooper Companies and gave the company a “buy” rating in a research note on Friday, December 5th. Robert W. Baird boosted their target price on shares of Cooper Companies from $85.00 to $98.00 and gave the company an “outperform” rating in a research report on Friday, December 5th. Barclays restated an “overweight” rating and issued a $91.00 price target on shares of Cooper Companies in a report on Monday, December 8th. Finally, Piper Sandler reiterated an “overweight” rating and set a $94.00 price objective (up previously from $83.00) on shares of Cooper Companies in a report on Friday, December 5th. Eight analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $90.31.

Cooper Companies Stock Down 1.8%

Cooper Companies stock opened at $81.29 on Friday. The firm has a market capitalization of $15.93 billion, a price-to-earnings ratio of 43.24, a price-to-earnings-growth ratio of 2.32 and a beta of 1.03. The firm’s fifty day moving average price is $80.24 and its two-hundred day moving average price is $74.03. The Cooper Companies, Inc. has a 1-year low of $61.78 and a 1-year high of $100.24. The company has a current ratio of 1.89, a quick ratio of 1.13 and a debt-to-equity ratio of 0.30.

Cooper Companies (NASDAQ:COO) last announced its quarterly earnings results on Thursday, December 4th. The medical device company reported $1.15 earnings per share for the quarter, beating the consensus estimate of $1.11 by $0.04. The business had revenue of $1.07 billion for the quarter, compared to analysts’ expectations of $1.06 billion. Cooper Companies had a net margin of 9.16% and a return on equity of 10.02%. The firm’s revenue for the quarter was up 4.6% compared to the same quarter last year. During the same quarter last year, the firm earned $1.04 EPS. Cooper Companies has set its FY 2026 guidance at 4.450-4.600 EPS and its Q1 2026 guidance at 1.020-1.040 EPS. On average, equities research analysts predict that The Cooper Companies, Inc. will post 3.98 earnings per share for the current fiscal year.

Insider Activity

In other news, Director Cynthia L. Lucchese purchased 1,784 shares of the company’s stock in a transaction that occurred on Monday, December 22nd. The shares were bought at an average cost of $84.06 per share, with a total value of $149,963.04. Following the completion of the transaction, the director directly owned 9,445 shares of the company’s stock, valued at approximately $793,946.70. This trade represents a 23.29% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Lawrence Erik Kurzius acquired 2,000 shares of Cooper Companies stock in a transaction on Wednesday, December 17th. The stock was purchased at an average cost of $82.50 per share, with a total value of $165,000.00. Following the completion of the transaction, the director directly owned 7,777 shares in the company, valued at $641,602.50. This represents a 34.62% increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last ninety days, insiders bought 16,014 shares of company stock worth $1,304,416. Company insiders own 1.98% of the company’s stock.

About Cooper Companies

Cooper Companies, Inc (NASDAQ: COO) is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company has grown through strategic acquisitions and organic development to become a major provider of vision care and women’s health products. Cooper Companies operates through two primary business segments—CooperVision and CooperSurgical—each serving specialized markets within the healthcare industry.

The CooperVision segment develops, manufactures and markets a broad range of soft contact lenses, as well as related accessories.